Volume 4, Issue 8, Part 3.
Raymond T. Chung, MD from Harvard Medical School interviews Dr. David Wyles from the University of California San Diego about his presentation: Sofosbuvir/Velpatasivr Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study, presented at the April 2016 EASL meeting.
Podcast (eviralhepatitis): Play in new window | Download
Subscribe: Apple Podcasts | Android | RSS